# US 2026/0250659 A1 · Method and systems for isolating nuclear rna from a high degradation tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0250659 A1
- Document ID: US20260250659A1
- Status: Published application
- Kind: A1
- Application number: 19/489,730
- Filed: 2024-06-06
- Published: 2026-08-27
- Earliest claimed: 2023-06-07
- Assignees: Case Western Reserve University
- Applicants: Case Western Reserve University
- Inventors: Paul J. Tesar; Marissa Scavuzzo
- Web page: https://patentgrep.com/patent/US20260250659A1

## CPC

- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- C12N 15/1017: {by filtration, e.g. using filters, frits, membranes}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6869: Methods for sequencing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention described herein provides an improved method and reagents to isolate nuclear RNA from high degradation tissues, such as duodenum, for use in, for example, high resolution transcriptome profiling and analysis.

## Claims

### Claim 1

A method for isolating nuclear RNA from a high degradation tissue, said method comprising:
i) incubating on ice the high degradation tissue reduced to a suitable size in a lysis buffer, for about 5-9 minutes (e.g., about 6-8 minutes, about 6.5-7.5 minutes, or about 7 minutes), wherein the lysis buffer comprises RNase inhibitor, protease inhibitor, buffer, osmotic stabilizer and ions to maintain/stabilize organelle membrane integrity, DNA precipitation reagent, chelating agent that quenches free Mg2+, and/or optionally anti-oxidant or reducing agent;
ii) homogenizing the high degradation tissue of the suitable size in the lysis buffer through sheer mechanical stress to generate a loosely homogenized tissue, wherein the sheer mechanical stress is generated by a Dounce-type homogenizer having a loose or Type-A pestle, through a total of about 15-25 passes (e.g., about 20 passes) of the Type-A pestle in the Dounce-type homogenizer, wherein the outer diameter of the Type-A homogenizer has a clearance from the inner diameter of the cylinder wall of between about 0.0025-0.0055 inches;
iii) adding a detergent mix, at about 6-10% (e.g., about 8%) volume of the lysis buffer, to the loosely homogenized tissue, wherein the detergent mix comprises about 4-6% or about 5% of IGEPAL CA-630-type nonionic, non-denaturing detergent in the lysis buffer;
iv) homogenizing the loosely homogenized tissue with the detergent mix in order to release organelles into said lysis buffer, using a tight or Type-B pestle in the Dounce-type homogenizer, by about 35-45 passes (e.g., about 40 passes) of the Type-B pestle in the Dounce-type homogenizer, wherein the outer diameter of the Type-B homogenizer has a clearance from the inner diameter of the cylinder wall of between about 0.0005-0.0025 inches;
v) filtering tissue lysates generated by step iv) through a strainer having a sieve size of about 40 μm to collect nuclei in the pass-through portion;
vi) adding an equal volume of a 50% iodixanol solution to the pass-through portion and vortexing to create a mixture having about 25% iodixanol;
vii) underlaying the mixture with an about 30% iodixanol solution and an about 40% iodixanol solution without disturbing the resulting three-layer iodixanol gradient;
viii) centrifuging the three-layer iodixanol gradient at about 10,000 g for 15-25 minutes (e.g., about 18 minutes) at about 4° C. with no brake;
ix) collecting nuclei from the interface(s) between the layers of the iodixanol gradient into a nuclei wash buffer for washing through vortexing, up to twice; and,
x) filtering washed nuclei through a 20 μm filter before pelleting the nuclei by centrifugation at about 500 g (e.g., for about 5 minutes at about 4° C.).

### Claim 2 (depends on 1)

The method of claim 1, wherein the high degradation tissue derives from a surgical resection or autopsy, or is rich in RNAses, proteases, enzymes, and/or ions (e.g., an enteric tissue, such as the most proximal region of the small intestine, duodenum, ileum, colon, or pancreas).

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the suitable size is no more than about 3 mm, 2 mm, or 1 mm in any dimension.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein step i) is about 7 minutes on ice, optionally with about 4 mL of the lysis buffer for a total tissue amount of less than about 15 mm in any dimension.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the lysis buffer comprises:
a) an RNase inhibitor selected from the group consisting of RNasin (e.g., about 0.25-1 U/μL, or about 0.5 U/μL of RNasin) and SUPERase RNAse Inhibitor (e.g., about 0.25-1 U/μL, or about 0.5 U/μL of SUPERase RNAse Inhibitor);
b) a protease inhibitor (e.g., complete, EDTA-free protease inhibitor);
c) a buffer that maintains pH at about 7.5-8 (e.g., about 20 mM Tricine-KOH, pH 7.8);
d) a DNA precipitation reagent selected from the group consisting of spermine tetrahydrochloride (e.g., about 0.15 mM spermine tetrahydrochloride) and spermidine trihydrochloride (e.g., about 0.5 mM spermidine trihydrochloride);
e) an osmotic stabilizer (such as 0.25 M sucrose);
f) ions to maintain/stabilize organelle membrane integrity (such as about 20-30 mM or about 25 mM KCl, and about 2.5-7.5 mM or about 5 mM MgCl 2);
g) a chelating agent to quench free Mg2+ (such as about 5-20 mM or about 10 mM citric acid); and,
h) an anti-oxidant or reducing agent (such as about 1 mM DTT).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the IGEPAL CA-630-type nonionic, non-denaturing detergent comprises IGEPAL CA-630 (octylphenoxypolyethoxyethanol) or Nonidet P-40 (NP-40).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the concentrations of the components of the lysis buffer remain substantially unchanged through steps i)-viii).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein step ix) is performed in about 10 ml of the nuclei wash buffer.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein step ix) consists of two washes, each in about 10 mL of the nuclei wash buffer.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, further comprising resuspending collected nuclei in the nuclei wash buffer for counting (e.g., in hemocytometer) and/or observation for quality control.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein said nuclei wash buffer comprises 1% serum albumin (such as BSA), an RNase inhibitor (such as RNasin (e.g., about 0.25-1 U/μL, or about 0.5 U/μL of RNasin) and/or SUPERase RNAse Inhibitor (e.g., about 0.25-1 U/μL, or about 0.5 U/μL of SUPERase RNAse Inhibitor)) in a buffer (such as PBS).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein nuclear RNA isolated by the method has an 28S RNA:18S RNA ratio of at least about 50, 55, 60, 65, 70, 75, 80, 85 or more.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of profiling transcriptome based on single nucleus RNA-sequencing (snRNA-seq), the method comprising:
1) isolating nuclear RNA using the method of any one of claims 1-12; and,
2) profiling transcriptome of the isolated nuclear RNA using single nucleus RNA-sequencing (snRNA-seq).

### Claim 14 (depends on 13)

The method of claim 13, wherein the nuclear RNA is isolated from a high degradation tissue that either derives from a surgical resection or autopsy, or is rich in RNAses, proteases, enzymes, and/or ions (e.g., an enteric tissue, such as the most proximal region of the small intestine, duodenum, ileum, colon, or pancreas).
